Ryan Bottegal

Ryan P. Bottegal focuses on complex patent litigation for clients in the pharmaceutical industry in Hatch-Waxman litigation and also for clients in consumer electronics litigation. Ryan earned his J.D. from the University of Baltimore School of Law. He received his bachelor’s degree from the University of Maryland.

EXPERIENCE :

• Secured a verdict in favor of Kyowa Kirin, Inc., a specialty pharmaceutical company that currently markets three products in the United States, after a five-day bench trial in federal court in which the largest generic pharmaceutical company in the world challenged a patent covering the client’s transdermal granisetron patch product. In securing this victory, we overcame the plaintiff’s contentions that there was no infringement, that the patent at issue was invalid, and that the patent was unenforceable.
• Represented Endo Pharmaceuticals Inc. and Strakan International S.à r.l. against Watson Labs’ attempt to make a generic version of Endo’s FORTESTA® product. Following a bench trial, the judge ruled in our clients’ favor on all contested issues and rejected the defendant’s claims of non-infringement, invalidity, and unenforceability. Successfully argued on appeal with the Federal Circuit affirming the trial court decision.
• Represented Apotex Inc. and Apotex Corp. in a patent infringement action regarding Apotex’s biosimilar applications to make biosimilar versions of Amgen’s NEULASTA® and NEUPOGEN® products. We navigated Apotex through the Biologics Price Competition and Innovation Act’s “patent dance,” and in the first BPCIA case to go to trial, we obtained a verdict of noninfringement. This result was affirmed on appeal to the U.S. Court of Appeals for the Federal Circuit.

EDUCATION :

• University of Baltimore School of Law, J.D., summa cum laude, 2013
• University of Maryland, B.S., summa cum laude, 2010

BAR ADMISSIONS : District of Columbia; Maryland

COURT ADMISSIONS :

• U.S. District Court — Maryland